Navigating risk stratification systems for the management of patients with GIST

Annals of Surgical Oncology

Volumn 18, Issue 6, 2011, Pages 1698-1704

  Patel, Shreyaskumar ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ARTICLE; CANCER ADJUVANT THERAPY; DIAGNOSTIC VALUE; GASTROINTESTINAL STROMAL TUMOR; GENOTYPE; HUMAN; INTESTINE TUMOR; MEDLINE; MITOSIS INDEX; NOMOGRAM; PROGNOSIS; RATING SCALE; RISK ASSESSMENT; RISK STRATIFICATION SYSTEM; STOMACH TUMOR; TUMOR LOCALIZATION; TUMOR VOLUME;

GASTROINTESTINAL STROMAL TUMORS; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 79956214975     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1496-z     Document Type: Article

References (36)

1. RP DeMatteo JJ Lewis D Leung, et al. 2000 Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival Ann Surg 231 51 58 10636102 10.1097/00000658-200001000-00008 1:STN:280: DC%2BD3c7gtVSmtQ%3D%3D (Pubitemid 30043939)
2. H Joensuu C Fletcher S Dimitrijevic, et al. 2002 Management of malignant gastrointestinal stromal tumours Lancet Oncol 3 655 664 12424067 10.1016/S1470-2045(02)00899-9 1:CAS:528:DC%2BD38Xotlygs7Y%3D (Pubitemid 35314908)
3. EA Perez AS Livingstone D Franceschi, et al. 2006 Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors J Am Coll Surg 202 623 629 16571433 10.1016/j.jamcollsurg.2006. 01.002
4. I Hassan YN You R Shyyan, et al. 2008 Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis Ann Surg Oncol 15 52 59 18000711 10.1245/s10434-007-9633-z
5. SC Lin MJ Huang CY Zeng, et al. 2003 Clinical manifestations and prognostic factors in patients with gastrointestinal stromal tumors World J Gastroenterol 9 2809 2812 14669339
6. B Nilsson P Bumming JM Meis-Kindblom, et al. 2005 Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden Cancer 103 821 829 15648083 10.1002/cncr.20862 (Pubitemid 40216412)
7. CD Fletcher JJ Berman C Corless, et al. 2002 Diagnosis of gastrointestinal stromal tumors: a consensus approach Hum Pathol 33 459 465 12094370 10.1053/hupa.2002.123545 (Pubitemid 34747864)
8. M Miettinen LH Sobin J Lasota 2005 Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up Am J Surg Pathol 29 52 68 15613856 10.1097/01.pas.0000146010.92933.de (Pubitemid 40023952)
9. M Miettinen J Lasota 2006 Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis Arch Pathol Lab Med 130 1466 1478 17090188 1:CAS:528:DC%2BD28XhtFyhs7%2FN (Pubitemid 44520713)
10. M Miettinen H Makhlouf LH Sobin J Lasota 2006 Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up Am J Surg Pathol 30 477 489 16625094 10.1097/00000478-200604000-00008 (Pubitemid 43740149)
11. CL Corless JA Fletcher MC Heinrich 2004 Biology of gastrointestinal stromal tumors J Clin Oncol 22 3813 3825 15365079 10.1200/JCO.2004.05.140 1:CAS:528:DC%2BD2cXhtVCitb%2FL (Pubitemid 41095223)
12. CL Corless MC Heinrich 2008 Molecular pathobiology of gastrointestinal stromal sarcomas Annu Rev Pathol 3 557 586 18039140 10.1146/annurev.pathmechdis. 3.121806.151538 1:CAS:528:DC%2BD1cXjsFersbw%3D (Pubitemid 351488293)
13. MC Heinrich BP Rubin BJ Longley JA Fletcher 2002 Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations Hum Pathol 33 484 495 12094373 10.1053/hupa.2002.124124 1:CAS:528:DC%2BD38XlslCls7s%3D (Pubitemid 34747867)
14. MC Heinrich CL Corless GD Demetri, et al. 2003 Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 21 4342 4349 14645423 10.1200/JCO.2003.04.190 1:CAS:528: DC%2BD2cXpsVWqu7Y%3D (Pubitemid 46621810)
15. S Hirota A Ohashi T Nishida, et al. 2003 Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors Gastroenterology 125 660 667 12949711 10.1016/S0016-5085(03)01046-1 1:CAS:528:DC%2BD3sXnvVSiur8%3D (Pubitemid 37070684)
16. J Martin A Poveda A Llombart-Bosch, et al. 2005 Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS) J Clin Oncol 23 6190 6198 16135486 10.1200/JCO.2005.19.554 1:CAS:528:DC%2BD2MXhtVKgtbrO
17. MC Heinrich K Owzar CL Corless, et al. 2008 Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group J Clin Oncol 26 5360 5367 18955451 10.1200/JCO.2008.17.4284 1:CAS:528: DC%2BD1MXhslCmug%3D%3D
18. CL Corless KV Ballman C Antonescu, et al. 2010 Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001 (abstract) J Clin Oncol 28 15 suppl 10006
19. RP DeMatteo KV Ballman CR Antonescu, et al. 2009 Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial Lancet 373 1097 1104 19303137 10.1016/S0140-6736(09)60500-6 1:CAS:528:DC%2BD1MXjslOltro%3D
20. H Joensuu 2008 Risk stratification of patients diagnosed with gastrointestinal stromal tumor Hum Pathol 39 1411 1419 18774375 10.1016/j.humpath.2008.06.025
21. HY Huang CF Li WW Huang, et al. 2007 A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome Surgery 141 748 756 17560251 10.1016/j.surg.2007.01.024 (Pubitemid 46856569)
22. C Mucciarini G Rossi F Bertolini, et al. 2007 Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study BMC Cancer 7 230 18096058 10.1186/1471-2407-7-230 (Pubitemid 351260308)
23. P Rutkowski ZI Nowecki W Michej, et al. 2007 Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor Ann Surg Oncol 14 2018 2027 17473953 10.1245/s10434-007-9377-9 (Pubitemid 46988258)
24. T Takahashi K Nakajima A Nishitani, et al. 2007 An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors Int J Clin Oncol 12 369 374 17929119 10.1007/s10147-007-0705-7 1:CAS:528:DC%2BD2sXhtFGgsb7L (Pubitemid 47573418)
25. RP DeMatteo JS Gold L Saran, et al. 2008 Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST) Cancer 112 608 615 18076015 10.1002/cncr.23199 (Pubitemid 351186201)
26. BK Goh PK Chow WM Yap, et al. 2008 Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria Ann Surg Oncol 15 2153 2163 18546045 10.1245/s10434-008-9969-z
27. P Rutkowski E Bylina A Wozniak, et al. 2010 Validation of Joensuu risk criteria for primary resectable gastrointestinal stromal tumors (abstract) J Clin Oncol 28 15 suppl 10018
28. PG Casali JY Blay 2010 Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 21 suppl 5 v98 v102 20555113 10.1093/annonc/mdq208
29. AP Dei Tos S Rossi L Messerini, et al. 2009 The natural history of imatinib-naive GIST: a retrospective analysis of 929 cases with long-term follow-up (abstract) J Clin Oncol 27 15 suppl 10555
30. JS Gold M Gonen A Gutierrez, et al. 2009 Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis Lancet Oncol 10 1045 1052 19793678 10.1016/S1470-2045(09)70242-6
31. European Medicines Agency. 2010. Glivec. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000406/human-med-000808.jsp&murl=menus/medicines/medicines.jsp&mid= WC0b01ac058001d124. Accessed September 2, 2010.
32. MH Cohen P Cortazar R Justice R Pazdur 2010 Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors Oncologist 15 300 307 20200041 10.1634/theoncologist.2009-0120 1:CAS:528:DC%2BC3cXlsFCltL4%3D
33. Clinical practice guidelines in oncology. Soft tissue sarcoma. V.2.2010. http://www.nccn.org/professionals/physician-gls/PDF/sarcoma.pdf. Accessed September 2, 2010.
34. I Ahmed NT Welch SL Parsons 2008 Gastrointestinal stromal tumours (GIST)-17 years experience from Mid Trent Region (United Kingdom) Eur J Surg Oncol 34 445 449 17320340 1:STN:280:DC%2BD1c7osFyktw%3D%3D (Pubitemid 351381282)
35. B Nilsson K Sjolund LG Kindblom, et al. 2007 Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST) Br J Cancer 96 1656 1658 17533389 10.1038/sj.bjc.6603797 1:CAS:528:DC%2BD2sXlvVShtrg%3D (Pubitemid 46847213)
36. J Martin-Broto A Gutierrez X Garcia-del-Muro, et al. 2010 Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study Ann Oncol 21 1552 1557 20231303 10.1093/annonc/mdq047 1:STN:280:DC%2BC3crmsVSqsQ%3D%3D